You are on page 1of 2

Federal Register / Vol. 67, No.

217 / Friday, November 8, 2002 / Notices 68145

Government and are available for locus, which has been designated HPC1 35 U.S.C. 207 to achieve expeditious
licensing in the U.S. in accordance with due to its putative link to hereditary commercialization of results of
35 U.S.C. 207 to achieve expeditious prostate cancer. HPC1 may lead to an federally-funded research and
commercialization of results of early, sensitive and accurate method for development. Foreign patent
federally-funded research and detecting cancer or a predisposition to applications are filed on selected
development. Foreign patent cancer, especially prostate cancer, in a inventions to extend market coverage
applications are filed on selected mammal. In addition, such claimed for companies and may also be available
inventions to extend market coverage methods can be used to monitor onset for licensing.
for companies and may also be available and progression of cancer, as well as a ADDRESSES: Licensing information and
for licensing. patient’s response to a particular copies of the U.S. patent applications
ADDRESSES: Licensing information and treatment. listed below may be obtained by writing
copies of the U.S. patent applications Signal Transduction Inhibitor to the indicated licensing contact at the
listed below may be obtained by writing Compounds in Clinical Trials as Cancer Office of Technology Transfer, National
to the indicated licensing contact at the Therapeutics Institutes of Health, 6011 Executive
Office of Technology Transfer, National Boulevard, Suite 325, Rockville,
Institutes of Health, 6011 Executive Elise C. Kohn, Lance A. Liotta, Maryland 20852–3804; telephone: 301/
Boulevard, Suite 325, Rockville, Christian C. Felder (NCI); 496–7057; fax: 301/402–0220. A signed
Maryland 20852–3804; telephone: 301/ U.S. Patent 5,359,078 issued October Confidential Disclosure Agreement will
496–7057; fax: 301/402–0220. A signed 25, 1994; be required to receive copies of the
Confidential Disclosure Agreement will U.S. Patent 5,482,954 issued January patent applications.
be required to receive copies of the 9, 1996;
patent applications. U.S. Patent 5,498,620 issued March Tissue Microosmometer
12, 1996; Ferenc Horkay, Peter J. Basser, Adam
New Gene Expressed in Prostate Cancer U.S. Patent 5,705,514 issued January Berman (NICHD)
and Methods of Use 6, 1998; DHHS Reference No. E–280–2002/0
TK Bera, C Wolfgang, I Pastan (NCI), U.S. Patent 5,880,129 issued March 9, filed Aug. 07, 2002
B Lee, J Vincent; 1999; Licensing Contact: Dale Berkley; 301/
DHHS Reference No. E–005–2002 Licensing Contact: Brenda Hefti; 301/ 435–5019; berkleyd@od.nih.gov
filed Nov. 14, 2001; 435–4632; heftib@od.nih.gov. This new tissue microosmometer
Licensing Contact: Jonathan Dixon; The above issued patents relate to allows for the quantification of minor
301/435–5559; dixonj@od.nih.gov. azole, diazole, and triazole compounds changes in the swelling properties of
A new polypeptide is described in that appear to inhibit signal different tissues (e.g. cartilage) using
this invention that is specifically transduction and inhibit invasion and very small amounts of tissue, and can be
detected in the cells of the prostate. This metastasis of malignant solid tumors. A used as a potential diagnostic technique
polypeptide has been termed Novel number of these compounds are in to detect early stages of cell or tissue
Gene Expressed In Prostate (NGEP). phase I, II and III clinical trials for injury such as cartilage degeneration or
There are potential claims to the NGEP specific indications, and might be useful disorder. Varying the vapor pressure in
gene, polynucleotides encoding NGEP, in other indications as well. the environment of the device induces
antibodies to NGEP, methods for using These issued patents claim a number controlled changes in the osmotic
an NGEP polypeptide, polynucleotide, of compositions of matter, pressure of a tissue layer attached to the
or antibody, and pharmaceutical pharmaceutical compositions of said surface of a flat quartz crystal. Variation
compositions containing any of the compounds, and methods of using said in the swelling degree is measured with
above NGEP-related molecules. This compounds. high sensitivity and reliability by
invention might be useful in prostate
Dated: November 4, 2002. monitoring the change in resonance
cancer diagnostics, such as an assay to
Jack Spiegel, frequency of the quartz crystal. The
detect prostate cancer, or as a
Director, Division of Technology, device requires less than one microgram
therapeutic directed towards prostate
Development and Transfer, Office of of sample, and the small tissue sample
cancer.
Technology Transfer, National Institutes of allows for an extremely fast response
Use of Interferon-Inducible 2’,5’- Health. time. The device is well suited to the
Oligoadenylate-Dependent RNase in the [FR Doc. 02–28536 Filed 11–7–02; 8:45 am] study of expensive or limited
Diagnosis, Prognosis, and Treatment of BILLING CODE 4140–01–P availability biological or
Prostate Cancer macromolecular samples.
J. Carpten (NHGRI), J. Trent (NHGRI), Method for Convection Enhanced
J. Smith, P. Walsh, W. Isaacs, D. DEPARTMENT OF HEALTH AND
HUMAN SERVICES Delivery of Therapeutic Agents
Stephan, and N. Nupponen (NHGRI);
PCT Application PCT/US02/19516 Edward H. Oldfield (NINDS)
National Institutes of Health DHHS Reference No. E–202–2002/0
(DHHS Ref. E–196–01/1), claiming
priority to a U.S. Provisional Patent filed Sep. 24, 2002
Government-Owned Inventions; Licensing Contact: Dale Berkley; 301/
Application filed on June 20, 2001; Availability for Licensing
Licensing Contact: Brenda Hefti; 301/ 435–5019; berkleyd@od.nih.gov
435–4632; heftib@od.nih.gov. AGENCY: National Institutes of Health, The invention is a method for
This invention pertains to the use of Public Health Service, HHS. monitoring the spatial distribution of
interferon-inducible 2’,5’- ACTION: Notice. therapeutic substances by MRI or CT
oligoadenlyate-dependent RNase L in that have been administered to tissue
the diagnosis, prognosis and treatment SUMMARY: The inventions listed below using convection-enhanced delivery, a
of cancer, particularly prostate cancer. are owned by agencies of the U.S. technique that is the subject of NIH-
The inventors have identified a Government and are available for owned U.S. Patent No. 5,720,720. In one
potential prostate cancer susceptibility licensing in the U.S. in accordance with embodiment, the tracer is a molecule,

VerDate 0ct<31>2002 16:24 Nov 07, 2002 Jkt 200001 PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 E:\FR\FM\08NON1.SGM 08NON1
68146 Federal Register / Vol. 67, No. 217 / Friday, November 8, 2002 / Notices

detectable by MRI or CT, which The invention is a method for integrase inhibitors that are derived
functions as a surrogate for the motion obtaining the centerline of a colon-like from diketo acids with a different anti-
of the therapeutic agent through the surface, which is an important tool for HIV mechanism from that of reverse
solid tissue. In other particular virtual colonoscopy. The invention uses transcriptase and protease inhibitors,
embodiments, the tracer is the only three steps: (1) Computing a these azide group-containing
therapeutic agent conjugated to an shrunken version of the colon surface compounds may represent potential
imaging moiety. The method of this (2) modeling the shrunken colon by an new therapeutics for treatment of
invention uses non-toxic ordered group of 3D points and (3) retroviral infections, including AIDS.
macromolecular MRI contrast agents selecting equally distanced planes to Dated: November 4, 2002.
comprised of chelated Gd(III). In define equal length segments along the
Jack Spiegel,
particular, the surrogate tracer used in centerline. The centerline is a vital
parameter for any virtual colonoscopy Director, Division of Technology,
this invention is a serum albumin Development and Transfer, Office of
conjugated with either a gadolinium technique as it defines a navigation path Technology Transfer, National Institutes of
chelate of 2-(p-isothiocyanotobenzyl)-6- along which the imaging proceeds and Health.
methyldiethylenetriamine pentaacetic it provides a natural coordinate system [FR Doc. 02–28537 Filed 11–7–02; 8:45 am]
acid or with iopanoic acid. These for describing polyp detections. A
BILLING CODE 4140–01–P
macromolecular imaging agents have virtual colonoscopy method is described
clearance properties that mimic the and claimed in NIH-owned U.S. Patent
pharmacokinetic properties of co- No. 6,246,784. However, detecting the DEPARTMENT OF HEALTH AND
administrated drugs, so as to be useful centerline of the colon is a challenging HUMAN SERVICES
in quantifying the range and dosage problem for which a number of
level of therapeutic drugs using MR approaches have been developed. Most National Institutes of Health
imaging. of these approaches are not fully
automatic, are slow and require the Government-Owned Inventions;
Refinement of Isointensity Surfaces original CT images. The method of this Availability for Licensing
Peter Yim (CC) invention is fully automatic, relatively
quick and uses only the 3D surface AGENCY: National Institutes of Health,
DHHS Reference No. E–078–2002/0 Public Health Service, DHHS.
filed Feb 22, 2002 rather than the original CT images.
ACTION: Notice.
Licensing Contact: Dale Berkley; 301/ Discovery of Novel Inhibitors of HIV–1
435–5019; berkleyd@od.nih.gov Integrase That Can Be Used for the SUMMARY: The inventions listed below
The invention is a method for Treatment of Retroviral Infection are owned by agencies of the U.S.
reconstructing arterial geometry from Including AIDS Government and are available for
magnetic resonance angiography (MRA) Terrence R. Burke, Jr., Xuechen Zhang, licensing in the U.S. in accordance with
using isosurfaces deformed to conform Godwin C. G. Pais, Christophe 35 U.S.C. 207 to achieve expeditious
to the boundaries of objects in the image Marchand, Evguenia Svarovskaia, commercialization of results of
with minimal a priori assumptions of Vinay K. Pathak, and Yves Pommier federally-funded research and
object shape. The method determines (NCI) development. Foreign patent
the degree of stenosis in digital DHHS Reference No. E–317–2001/0 applications are filed on selected
phantoms with an accuracy of at least filed Dec. 07, 2001 inventions to extend market coverage
10%. This method, unlike previous Licensing Contact: Sally Hu; 301/435– for companies and may also be available
techniques, does not require the 5606; hus@od.nih.gov for licensing.
imposition of a pre-defined surface This invention provides azido group- ADDRESSES: Licensing information and
mesh onto the image or user interaction containing diketo acids that can inhibit copies of the U.S. patent applications
for definition of the vessel axes. Here, HIV–1 integrase in vitro efficiently listed below may be obtained by writing
the deformable model surface mesh is while being highly selective for the to the indicated licensing contact at the
generated by the isosurface algorithm. strand transfer step of the integration Office of Technology Transfer, National
Accordingly, the new method requires reaction. Human Immunodeficiency Institutes of Health, 6011 Executive
minimal user interaction and provides Virus (HIV) and other retroviruses Boulevard, Suite 325, Rockville,
highly accurate results when applied to require three viral enzymes for Maryland 20852–3804; telephone: 301/
the evaluation of vascular stenoses. The replication: Reverse transcriptase, 496–7057; fax: 301/402–0220. A signed
methodology may also be applicable for protease and integrase. The prognosis of Confidential Disclosure Agreement will
reconstruction of the geometry of AIDS has been improved recently by the be required to receive copies of the
vascular aneurysms from MRA. Other discovery and application of reverse patent applications.
potential applications include precision transcriptase and protease inhibitors.
surface reconstruction of vascular However, a significant fraction of Regulation of INS (3456) P4 Signalling
surfaces from computed tomographic patients fail to respond to such by a Reversible Kinase/Phosphatase
angiography (CTA) and precision treatments and viral resistance remains and Methods and Compositions Related
reconstruction of the surface of the a major problem. Furthermore, anti- Thereto
colon from computed tomography (CT). AIDS combinations are often not well Dr. Stephen Shears (NIEHS)
tolerated. Thus, HIV integrase is a DHHS Reference No. E–105–2002/0
Automated Centerline Detection filed Mar 18, 2002
rational target for AIDS therapy because
Algorithm for Colon-Like 3D Surfaces Licensing Contact: Marlene Shinn; 301/
genetic studies demonstrated that the
Gheorghe Iordanescu (CC), Ronald enzyme is essential for viral replication 435–4426; shinnm@od.nih.gov.
Summers (CC), Juan Cebral while being without a cellular Signaling entities are frequently
DHHS Reference No. E–311–2001 filed equivalent. Therefore, specific integrase controlled by quite delicate shifts in the
Dec. 27, 2001 inhibitors should be effective and dynamic balance of regulatory signals
Licensing Contact: Dale Berkley; 301/ devoid of toxicity. Since this invention with competing impacts. Ion channels
435–5019; berkleyd@od.nih.gov involves the discovery of novel HIV–1 provide particularly impressive

VerDate 0ct<31>2002 16:24 Nov 07, 2002 Jkt 200001 PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 E:\FR\FM\08NON1.SGM 08NON1